Regeneron files Eylea for DME indication

Share this article:

Regeneron announced today that the FDA has accepted Eylea's supplemental Biologics License Application for the treatment of diabetic macular edema (DME). The goal for a standard review of an sBLA is 10 months from submission, for a target action date of August 18, 2014. The submission is based off positive results from the company's Phase 3 VIVID and VISTA trials.

Eylea was approved in the US for the treatment of neovascular (wet) age-related macular degeneration (AMD) in November 2011 and for macular edema following central retinal vein occlusion (CRVO) in September 2011. Bayer and Regeneron are collaborating on the global development of the drug. Regeneron holds exclusive rights in the US, while Bayer has exclusive marketing rights ex-US. Both companies will share equal profits from sales of Eylea except for Japan, where Regeneron receives a royalty.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.